Balanced Pharma Inc.
Less Painful, Faster-Acting Dental Injections
On a Mission to Improve Patient Comfort
Invest in a Better Dental Anesthetic
$4.00
Price Per Share
$996
Minimum Investment
Non-Voting Common Stock
Securities Offered
Company Overview
Dental Injections are Unnecessarily Painful and Slow-Acting
Dentists report that current dental injections have a 20% average failure rate4
58% of patients believe the injection is the worst part of the dental experience1
86% of patients want a less-painful dental injection2
90% of dentists want an improved dental anesthetic3
Each Year, Patients Suffer Nearly 2 Billion Dental Injections6
These injections are stressful for both patients and dentists, and for a good reason:
- The acid preservative in local anesthetic drugs causes pain during injection and a delayed anesthetic effect.
- Local anesthetic pH can be 25,000 times more acidic than human tissue.
- For dentists, this means uncomfortable patients, wasted time, and wasted money.
Each Year, Patients Suffer Nearly 2 Billion Dental Injections6
These injections are stressful for both patients and dentists, and for good reason:
- The acid preservative in local anesthetic drugs causes pain during injectionand a delayed anesthetic effect.
- Local anesthetic pH can be 25,000 times more acidic than human tissue.
- For dentists, this means uncomfortable patients, wasted time, and wasted money.
On a Mission to Improve Patient Comfort
Invest in a Better Dental Anesthetic
Dr. Scott Keadle, a dentist for over 30 years, experienced firsthand the limitations of current dental anesthetic drugs and their inability to provide a fast-acting, reliable, and painless injection.
He wanted a better anesthetic for his patients: Less injection pain, less waiting time, and more reliability.
Dr. Keadle invented patented technology to enable pH-balanced versions of the most common local anesthetics, using a standard syringe and protocol. He then presented the opportunity to a group of dentists who invested over $1 million to help found Balanced Pharma Incorporated (BPI).
Now he leads a team of industry experts committed to bringing the first-ever pH-balanced dental anesthetic to market.
On a Mission to Improve Patient Comfort
Invest in a Better Dental Anesthetic
Dr. Scott Keadle, a dentist for over 30 years, experienced firsthand the limitations of current dental anesthetic drugs and their inability to provide a fast-acting, reliable, and painless injection.
He wanted a better anesthetic for his patients: Less injection pain, less waiting time, and more reliability.
Dr. Keadle invented patented technology to enable pH-balanced versions of the most common local anesthetics, using a standard syringe and protocol. He then presented the opportunity to a group of dentists who invested over $1 million to help found Balanced Pharma Incorporated (BPI).
Now he leads a team of industry experts who are committed to bringing the first-ever pH-balanced dental anesthetic to market.
Products & Services
Introducing Libracaine® Dental
LIDOCAINE HCL 2% / EPINEPHRINE 1:100,000 / SODIUM BICARBONATE 0.7%9
The First and Only pH-Balanced Dental Anesthetic in the Convenience of a Standard Dental Cartridge
- Less painful, faster-acting, more reliable5
- Patented cartridge technology7
- 505(b)(2) abbreviated FDA regulatory pathway
- A pH-balanced version of the most often-used anesthetic in dentistry4
- Same safety profile, same 24-month shelf life
- No new equipment, no new protocols
- Supplied in a standard dental cartridge
Peer Testimonial
"A pH-balanced anesthetic in a standard dental cartridge will be a game changer.."
Jason Goodchild, DMDDr. Goodchild is Vice President of Clinical Affairs at Premier Dental Products and holds academic appointments at the University of Pennsylvania School of Dental Medicine, Rutgers School of Dental Medicine, and Creighton University School of Dentistry. He has authored more than 50 research papers on dental pain management.
”"A pH-balanced anesthetic in a standard dental cartridge will be a game changer.."
Jason Goodchild, DMDDr. Goodchild is Vice President of Clinical Affairs at Premier Dental Products and holds academic appointments at the University of Pennsylvania School of Dental Medicine, Rutgers School of Dental Medicine, and Creighton University School of Dentistry. He has authored more than 50 research papers on the subject of dental pain management.
The Team
Committed to Excellence in Patient Comfort
John Scott Keadle
Chairman & CEO
Founder & CEO at Balanced Pharma, 30+ years as a dentist, practice owner & business executive.
John Selig
Board Director
Managing Partner at WaveEdge Capital, 25+ years in life science investment banking and M&A practice.
Mark Sebree
Board Director, Chief Development Officer
35+ years of experience establishing and implementing strategy in the pharmaceutical industry.
Deal Terms
$4.00 per share (Minimum: 249 shares)
Raise Target:$25M
All Investors Welcome (All income and wealth levels)
Fundraising Description
| Securities offered: | 6,250,000 shares of Common Stock
|
|
Common Stock outstanding immediately before the Offering(1) |
20,610,000 |
|
Common Stock outstanding immediately after the Offering, assuming a fully subscribed Offering(2)(3) |
26,860,000 |
Use of Funds
| $5M | $7.5M | $15M | $25M | |
| Gross Proceeds to the Company | $5.00 | $7.50 | $15.00 | $25.00 |
| Estimated offering fees and expenses | $400,000 | $550,000 | $850,000 | $1,252,000 |
| Net Proceeds | $4,600,000 | $6,950,000 | $14,150,000 | $23,748,000 |
| Product Development | $900,000 | $1,300,000 | $1,300,000 | $2,300,000 |
| Product Manufacturing | $1,700,000 | $2,000,000 | $4,000,000 | $7,000,000 |
| Product Marketing & Disease Awareness | $ -- | $500,000 | $3,700,000 | $7,350,000 |
| Fundraising | $1,000,000 | $1,250,000 | $2,750,000 | $3,598,000 |
| Intellectual Property Development | $200,000 | $300,000 | $300,000 | $400,000 |
| General & Administrative | $800,000 | $1,600,000 | $2,100,000 | $3,100,000 |
| Total net use of proceeds | $4,600,000 | $6,950,000 | $14,150,000 | $23,748,000 |
|---|
Risks and Disclosures
Investing in start-ups or early developmental companies is risky. You should be prepared to lose your investment or wait a significant time before realizing any economic benefit from it. Therefore, you must consider your immediate and future income needs and invest no more than you can afford to lose.
Securities purchased in a crowdfunding transaction generally cannot be resold for a specific period, unless certain conditions are met. We encourage you to thoroughly read all offering documentation and refer to our FAQs to ensure you are familiar with the characteristics of the types of securities JUSTLY offers and the associated risks. Please ensure you understand the terms of what you are investing in before investing.
Documents
Offering Circular (1 File)
Offering Circular Supplement (1 File)
Updates
Check back here for the latest news!
FAQs
Making an Investment in Balanced Pharma Inc.
When you complete your investment on JUSTLY, your money will be transferred to an escrow account where an independent escrow agent will watch over your investment until it is accepted by the issuer. Once the Issuer accepts your investment and specific regulatory procedures are completed, your money will be transferred from the escrow account to the Issuer in exchange for your securities.
To make an investment, you will need the following information readily available:
- Personal information such as your current address and phone number
- Employment and employer information
- Net worth and income information
- Your accredited investor status
- Social Security Number or passport
- ABA bank routing number and checking account number (typically found on a personal check or bank statement) or debit card information, unless paying via a Wire transfer.
When you complete your investment on JUSTLY, your money will be transferred to an escrow account where an independent escrow agent will watch over your investment until it is accepted by the issuer. Once the Issuer accepts your investment and specific regulatory procedures are completed, your money will be transferred from the escrow account to the Issuer in exchange for your securities.
To make an investment, you will need the following information readily available:
- Personal information such as your current address and phone number
- Employment and employer information
- Net worth and income information
- Your accredited investor status
- Social Security Number or passport
- ABA bank routing number and checking account number (typically found on a personal check or bank statement) or debit card information, unless paying via a Wire transfer.
After My Investment
Currently, there is no market or liquidity for these securities. Right now, the Issuer does not plan to list these securities on a national exchange or another secondary market. At some point, the Issuer may choose to do so, but until then you should plan to hold your investment for a significant period of time before a “liquidation event” occurs. A “liquidation event” is when the Issuer either lists their securities on an exchange, is acquired, or goes bankrupt.
You can view your portfolio of investments within your upon initiating your investment. If the offering closes successfully and you are accepted as a shareholder/investor, you may receive periodic updates from the Company.
Currently, there is no market or liquidity for these securities. Right now, the Issuer does not plan to list these securities on a national exchange or another secondary market. At some point, the Issuer may choose to do so, but until then you should plan to hold your investment for a significant period of time before a “liquidation event” occurs. A “liquidation event” is when the Issuer either lists their securities on an exchange, is acquired, or goes bankrupt.
You can return to JUSTLY at any time to view your portfolio of investments and obtain a summary statement. If invested under Regulation CF you may also receive periodic updates from the company about their business, in addition to monthly account statements.
Contact
18204 Mainsail Pointe Dr.
Cornelius, NC 28031
(980) 231-4318
[email protected]
balancedpharma.com
Contact
18204 Mainsail Pointe Dr.
Cornelius, NC 28031
(980) 231-4318
[email protected]
balancedpharma.com
(1) “58% OF PATIENTS BELIEVE THE INJECTION IS THE WORST PART OF THE DENTAL EXPERIENCE,” OLSON RESEARCH GROUP, “PATIENT DENTAL CARE STUDY QUANTITATIVE REPORT, CONDUCTED FOR BALANCED PHARMA, MAY 7, 2021,” FIELDING: MARCH 30–APRIL 23, 2021, TOTAL SAMPLE SIZE: N=140 (INCLUDES 40 PARENTS/CAREGIVERS)
(2) “WHAT PATIENTS WANT: A LESS-PAINFUL DENTAL INJECTION: 86%,” OLSON RESEARCH GROUP, “PATIENT DENTAL CARE STUDY QUANTITATIVE REPORT, CONDUCTED FOR BALANCED PHARMA, MAY 7, 2021,” FIELDING: MARCH 30–APRIL 23, 2021, TOTAL SAMPLE SIZE: N=140 (INCLUDES 40 PARENTS/CAREGIVERS)
(3) “OVER 90% OF DENTISTS REPORT A DESIRE FOR CURRENT ANESTHETICS TO BE MORE RELIABLE, LESS PAINFUL, OR FASTER ACTING,” OLSON RESEARCH GROUP, “DENTIST QUANTITATIVE REPORT, CONDUCTED FOR BALANCED PHARMA, AUGUST 13, 2021,” FIELDING: JUNE 18–JULY 19, 2021, TOTAL SAMPLE SIZE: N=181;
(4) “DENTISTS REPORT AN INITIAL ANESTHETIC FAILURE RATE OF 20%,” OLSON RESEARCH GROUP, “DENTIST QUANTITATIVE REPORT, CONDUCTED FOR BALANCED PHARMA, AUGUST 13, 2021,” FIELDING: JUNE 18–JULY 19, 2021, TOTAL SAMPLE SIZE: N=181
(5) 2018 META-ANALYSIS: SIGNIFICANTLY DECREASED ONSET TIME AND INJECTION PAIN; GUO ET AL FROM UNIVERSITY OF SOUTHERN CALIFORNIA SCHOOL OF DENTISTRY CONCLUDED: “BUFFERED LIDOCAINE SIGNIFICANTLY DECREASED ONSET TIME AND INJECTION PAIN (VAS) COMPARED WITH NON-BUFFERED LIDOCAINE IN INFERIOR ALVEOLAR NERVE BLOCK.”; 2017 CLINICAL STUDY: REDUCES THE PAIN ON INJECTION; PHERO ET AL FROM UNIVERSITY OF NORTH CAROLINA SCHOOL OF DENTISTRY CONCLUDED: “BUFFERED LIDOCAINE REDUCES THE PAIN ON INJECTION WITH A MAXILLARY FIELD BLOCK AND RESULTS IN SIMILAR LENGTHS OF PULPAL ANESTHESIA AS NON-BUFFERED 2% LIDOCAINE.” 2017 CLINICAL STUDY: LOWER PAIN ON INJECTIONS. WARREN ET AL FROM UNIVERSITY OF NORTH CAROLINA SCHOOL OF DENTISTRY CONCLUDED: “AFTER MANDIBULAR NERVE BLOCK, BUFFERED 1% LIDOCAINE CAN PRODUCE SIMILAR DURATION OF PULPAL ANESTHESIA AS NON-BUFFERED 2% LIDOCAINE AND LOWER PAIN ON INJECTIONS.”; 2019 META-ANALYSIS: 2.29 TIMES MORE RELIABLE IN INFLAMED TEETH; KATTAN ET AL FROM UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTISTRY CONCLUDED: “BUFFERED LOCAL ANESTHETICS HAVE 2.29 TIMES GREATER LIKELIHOOD OF ACHIEVING SUCCESSFUL ANESTHESIA [IN PULPALLY INVOLVED TEETH].”
(6) SDM NORTHCOAST, LLC REPORT, “INJECTABLE CARPULES MARKET SIZE ANALYSIS, UNITED STATES, CANADA, MEXICO, 2019 UNITS”, JULY 15, 2021; KEY-STONE RESEARCH, “EUROPEAN LOCAL ANESTHETICS MARKET SURVEY,” SEPTEMBER 20, 2021; BALANCED PHARMA INTERNAL ESTIMATES
(7) BPI OWNS THE FOLLOWING GRANTED PATENTS AND PENDING PATENT APPLICATIONS: U.S. PATENT NO. 11,305,064 (ISSUED APRIL 19TH, 2022); U.S. APPLICATION NO. 17/722,016; INTERNATIONAL PCT APPLICATION NO. PCT/IB2018/052598; CANADIAN APPLICATION NO. 3,111,347 (CANADIAN NATIONAL PHASE OF PCT/IB2018/052598); EUROPEAN APPLICATION NO. 18897951.2 (EUROPEAN REGIONAL PHASE OF PCT/IB2018/052598); JAPANESE APPLICATION NO. 2020-556351 (JAPANESE NATIONAL PHASE OF PCT/IB2018/052598); KOREAN APPLICATION NO. 10-2020-7021685 (REPUBLIC OF KOREA NATIONAL PHASE OF PCT/IB2018/052598); U.S. APPLICATION NO. 16/655,362; U.S. APPLICATION NO. 63/233,879; BPI ALSO OWNS ONE TRADEMARK APPLICATION, U.S. APPLICATION NO. 88/198,808, PENDING FOR THE LIBRACAINE MARK.
(8) OLSON RESEARCH GROUP, “U.S. DENTIST QUANTITATIVE REPORT, CONDUCTED FOR BALANCED PHARMA, AUGUST 13TH, 2021,” TOTA SAMPLE SIZE: 181 DENTISTS; KEY-STONE RESEARCH, “EUROPEAN LOCAL ANESTHETICS MARKET SURVEY, CONDUCTED FOR BALANCED PHARMA, SEPTEMBER 20, 2021,” TOTAL SAMPLE SIZE: 433 DENTISTS
(9) LIBRACAINE HAS NOT YET BEEN APPROVED BY FDA AND IS NOT AVAILABLE FOR SALE.
(10) BPI HAS NOT YET BEGUN TRIALS TO DETERMINE WHETHER ITS TECHNOLOGY CAN ADAPT TO DERMATOLOGY, PLASTIC SURGERY, EMERGENCY MEDICINE, INTERVENTIONAL RADIOLOGY, AND PODIATRY.
Comments